Comparer des méthodes

	Échelle Visuelle Analogique de Prurit (EVA Prurit)	EASI (Eczema Area and Severity Index)	Indice SCORAD (SCORing Atopic Dermatitis)
Domaine	Dermatologie	Dermatologie	Dermatologie
Famille	Process / pipeline	Process / pipeline	Process / pipeline
Année d'origine	1983 (VAS); widely adopted for pruritus 1990s–2000s	2001	1993
Auteur d'origine	Huskisson EC (VAS methodology); adapted for pruritus in dermatology	Hanifin JM, Thurston M	European Task Force on Atopic Dermatitis (ETFAD)
Type	Self-report	Clinician-rated	Clinician-rated
Source fondatrice	Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587-593.	Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18.	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.
Alias	Itch VAS, Pruritus Severity Scale	EASI Index	SCORAD Index
Apparentées	3	2	3
Résumé	The Pruritus Visual Analog Scale (VAS) is a simple, single-item patient-administered tool measuring itch intensity on a continuous 0–10 (or 0–100) scale. Adapted from the original VAS for pain, it is one of the most frequently used outcome measures in dermatological research and clinical practice due to its simplicity, brevity, and responsiveness to treatment. Pruritus VAS is essential in trials of antipruritic therapies and in conditions where itching is a primary complaint (atopic dermatitis, psoriasis, pruritus ani, lichen planus).	The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA).	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.